When does Rituxan Hycela’s patent expire?
Public patent-expiry timing depends on which specific patent(s) cover Rituxan Hycela (rituximab and hyaluronidase formulation/uses) and where the filing occurred. Patent terms also differ by jurisdiction and by whether there are any patent term adjustments or extensions.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs, including Rituxan/Hycela-related coverage. Checking Rituxan Hycela on DrugPatentWatch is the most direct way to see the specific patents listed for expiry (and the latest projected dates based on those filings): DrugPatentWatch: Rituxan Hycela.
What is the difference between “patent expiry” and “exclusivity expiry”?
Even after patents expire, regulators may still require a period of regulatory exclusivity (for example, data exclusivity or market exclusivity tied to approval pathways). Those exclusivity periods can delay generic or biosimilar entry past the end of the last relevant patent.
To get the exact dates that matter for market entry, you generally need both:
- the last relevant patent expiry for the product/formulation/claims, and
- any regulatory exclusivity listed for the branded reference product.
DrugPatentWatch’s listings often help separate “patent expiry” vs “exclusivity” depending on how the site tracks each element: DrugPatentWatch: Rituxan Hycela.
Are biosimilars affected by Rituxan Hycela patent dates?
Rituxan Hycela is a biologic/antibody product, so competition typically comes from biosimilars. Biosimilar approval and launch timing can depend on:
- patent litigation and the “patent landscape” for the reference product, and
- the regulatory exclusivity/patent protections in force at the time of potential launch.
If your goal is “when can competitors sell,” you want the latest date among the relevant patents and any exclusivity—rather than an early patent date.
Which Rituxan Hycela patents should you check for expiry?
For a formulation like Rituxan Hycela, the patents that matter most are usually those tied to:
- the specific combination/product formulation (rituximab with hyaluronidase),
- the dosing/administration method,
- and any protected use claims.
On a patent-expiry lookup site, these appear as multiple individual patents with different projected expiry dates. The “last to expire” is often the controlling one for launch timing.
Use the DrugPatentWatch entry to see the specific patent numbers and their expiry projections: DrugPatentWatch: Rituxan Hycela.
If you meant non-US expiry (Europe/UK/Canada), the dates will differ
Patent term is jurisdiction-specific. A US patent expiry date won’t necessarily match:
- Europe (EPO/EP patents, with different rules),
- UK (after Brexit rules),
- Canada (including Canadian patent term adjustments and regulatory linkage),
- or other countries.
If you tell me the country/region you care about, I can help you interpret which “expiry” timeline to use and what to look for.
Source